menu
    • menu
    [{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Tau Medical \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"||Alpha-radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alpha Tau Medical \/ Medison Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau Medical \/ Medison Pharma"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Linc AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncoinvent \/ Linc AB","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Linc AB"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau Medical \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Radium-224

    Menu

    Radium-224

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oncoinvent

                            Norway arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Oncoinvent

                            Norway arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oncoinvent Reports Promising Interim Radspherin® Data for Peritoneal Carcinomatoses

                            Details : Radspherin is a novel alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities. It is under development for peritoneal carcinomatosis from ovarian cancer.

                            Product Name : Radspherin

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 11, 2024

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oncoinvent

                            Norway arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Oncoinvent

                            Norway arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oncoinvent Doses First Patient in Radspherin® Phase 2 Trial For Ovarian Cancer

                            Details : RAD-18-002 (Radspherin), is a novel alpha-emitting radioactive microsphere, which is under clinical development for treatment of peritoneal carcinomatosis from ovarian cancer.

                            Product Name : Radspherin

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 10, 2024

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Oncoinvent

                            Norway arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Oncoinvent

                            Norway arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oncoinvent Receives FDA Fast Track for Radspherin® in Ovarian Cancer Treatment

                            Details : RAD-18-002 (Radspherin), is a novel alpha-emitting radioactive microsphere, which is under clinical development for treatment of peritoneal carcinomatosis from ovarian cancer.

                            Product Name : Radspherin

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 24, 2024

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Oncoinvent

                            Norway arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Oncoinvent

                            Norway arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Linc AB

                            Deal Size : $11.7 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Oncoinvent ASA Announces Oversubscribed Private Placement

                            Details : The net proceeds from the financing will be used for the advancement of Radspherin (Alpha-emitting Radionuclide) for the treatment of peritoneal metastases originating from ovarian cancer.

                            Product Name : Radspherin

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 12, 2024

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Linc AB

                            Deal Size : $11.7 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Oncoinvent

                            Norway arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Oncoinvent

                            Norway arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin® in Ovar...

                            Details : RAD-18-002 (Radspherin), is a novel alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities. It is under phase 1/2 clinical development for treatmemt of peritoneal carcinomatosis from ovarian cancer.

                            Product Name : Radspherin

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 31, 2023

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Oncoinvent

                            Norway arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Oncoinvent

                            Norway arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin® in Colo...

                            Details : Radspherin (alpha-emitting radioactive micro particle suspension) is a novel treatment principle especially designed to give local radiation to the surface of the abdominal cavity. It is being evaluated for patients with peritoneal carcinomatosis from co...

                            Product Name : Radspherin

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 27, 2023

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Alpha Tau Medical

                            Israel arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Alpha Tau Medical

                            Israel arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT

                            Details : Alpha Dart (radium-224) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources.

                            Product Name : Alpha Dart

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 17, 2023

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Alpha Tau Medical

                            Israel arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Alpha Tau Medical

                            Israel arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alpha Tau Announces Grant of Expanded Radioactive License and Final Pre-Clinical Laboratory Regulatory Approva...

                            Details : Alpha DaRT (radium-224) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays it emitts high-energy alpha particles with the goal of destroyi...

                            Product Name : Alpha Dart

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 03, 2023

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Alpha Tau Medical

                            Israel arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Alpha Tau Medical

                            Israel arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metas...

                            Details : Alpha DaRT (radium-224) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays it emitts high-energy alpha particles with the goal of destroyi...

                            Product Name : Alpha Dart

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 03, 2023

                            Lead Product(s) : Radium-224

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Alpha Tau Medical

                            Israel arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Alpha Tau Medical

                            Israel arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radium-224,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Acceptance in Major Peer-Reviewed Journals of Two Landmark Pre-Clinical Studies

                            Details : Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources.

                            Product Name : Alpha Dart

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 09, 2022

                            Lead Product(s) : Radium-224,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth